NCT01124747CompletedPhase 1
An Open-Label Study to Evaluate the Disposition of 14C-Labeled ASP1585 in Healthy Male Volunteers
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Astellas Pharma Inc
- Enrollment
- 12
- Primary Endpoint
- Excretion of radioactivity in urine
Study Overview
Brief Summary
The objective of this study is to assess the systemic disposition of ASP1585 after oral administration of 14C-labeled drug in healthy male subjects.
Detailed Description
Subjects will receive study drug for 18 days with a radioactive dose of study drug given on Day 15. Blood, urine and feces will be collected to confirm recovery of radioactivity.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 55 Years (Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Body Mass Index (BMI) between 18 and 32 kg/m2, inclusive and minimum body weight 45 kg
- •Agrees to sexual abstinence or to use a highly effective form of birth control which includes a barrier method throughout the study
- •In good health
Exclusion Criteria
- •History of any clinically significant disease
- •History of bowel obstruction, swallowing disorders, gastrointestinal disorders, gastrointestinal surgery, actively bleeding hemorrhoids, or gastric/duodenal ulcers
- •Irregular bowel habits (<1 bowel movement per day)
- •Clinically significant illness within 30 days
- •Received any drug or medicine (prescription or over-the-counter), including topical medications, complementary and alternative medicines and vitamin and mineral supplements within 14 days prior to the first dose of study drug
- •Received any investigational medication during the last 30 days or 5 half-lives, whichever is longer, prior to screening
- •Consumes >10 units of alcohol per week or history of alcoholism or drug/chemical abuse within past 2 years
- •Smokes cigarettes or other nicotine-containing products
- •Anticipates an inability to abstain from alcohol use for 48 hours prior to first dose of study drug or from grapefruit, Seville oranges, star fruit or products containing these items from 72 hours prior to first dose of study drug until end of study
- •Positive drug or alcohol screen at Screening or Day -1
- •Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or gamma-glutamyl transferase (GGT) value of >2x upper limit of normal at Screening or Day -1
- •Known positive for human immunodeficiency virus (HIV), Hepatitis A, Hepatitis B or Hepatitis C
- •Unwilling or unable to swallow large numbers of capsules
- •Significant blood loss, donated one unit of blood or more, or received a transfusion of any blood or blood product within 60 days or donated plasma within 7 days prior to Day -1
- •Known cumulative radiation exposure >5 rems for the whole body, active blood forming organs, ocular lens, and gonads, and >15 rems for other organs
- •Has had nuclear medicine procedures, computed tomography scans, or significant x-rays (other than dental) within the past 12 months, has received radiolabeled material within the last 6 months, or has had significant occupational radiation exposure
- •Has participated in a radiolabled study within the last 6 months or participated in more than one radiolabeled study within the last 12 months
Arms & Interventions
ASP1585 and 14C-Labeled ASP1585
Experimental
Intervention: ASP1585 (Drug)
ASP1585 and 14C-Labeled ASP1585
Experimental
Intervention: 14C-Labeled ASP1585 (Drug)
Outcomes
Primary Outcomes
Excretion of radioactivity in urine
Time Frame: Day 15 and up to Day 24
Excretion of radioactivity in feces
Time Frame: Day 15 and up to Day 24
Secondary Outcomes
- Radioactivity assessment through analysis of blood samples(Day 15 and up to Day 24)
Investigators
Similar Trials
Terminated
Phase 2
An Open-Label Study of Apabetalone in Covid InfectionCOVID-19 InfectionNCT04894266Resverlogix Corp1
Completed
Phase 1
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 AntigenAdvanced MalignanciesAdvanced CancerNCT04837196Astellas Pharma Global Development, Inc.24
Completed
Phase 1
Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid LeukemiaAcute Myeloid Leukemia (AML)NCT02181660Astellas Pharma Inc24
Completed
Phase 1
A Pharmacokinetic and Bioavailability Study of 28431754 (Canagliflozin) in Healthy Male VolunteersHealthyNCT01157000Johnson & Johnson Pharmaceutical Research & Development, L.L.C.9
Completed
Phase 3
Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung CancerNon-Small-Cell Lung CancerNCT00049998GlaxoSmithKline760